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Abstract
People with schizophrenia are more likely to die prematurely than the general population from both suicide and physical ill health. Published studies
examining the incidence of cancer in schizophrenia patients report increased, reduced or similar incidence compared with the general population. Older
studies tended to report lower incidence rates which fuelled speculation as to the biological and other mechanisms for this protective effect.
Furthermore, mortality rates in patients with schizophrenia appear higher than expected. We undertook a non-systematic review of published data
to give an overview for these variable findings and illustrate methodological confounders by highlighting a systematic review of breast cancer studies.
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Introduction
People with schizophrenia have a life expectancy 15–20 years
shorter than the general population in developed countries
(Hennekens et al., 2005). This mortality gap also appears to
be increasing, suggesting that people with schizophrenia are
not beneﬁting from advances in healthcare to the same extent
as the general population. This increased mortality was ini-
tially attributed to suicide, but the incidence of suicide cannot
account for this mortality gap. Indeed, a recent epidemiolog-
ical study reported that only one-third of subjects with schizo-
phrenia attempted to harm themselves (Karagianis et al.,
2009). In general, this excess mortality is attributable to
cardiovascular, neoplastic and respiratory disease (Leucht
et al., 2007).
The physical health of schizophrenia patients has
received increasing attention (Barnett et al., 2007; Osborn
et al., 2007; Smith et al., 2007). Much of that interest has
focused on metabolic and cardiovascular disease, with many
guidelines being published on the speciﬁc management and
detection of these disorders in those with serious mental ill-
ness (SMI) (Lehman et al., 2004; Taylor et al., 2007).
However, the relationship between cancer and schizophrenia
is not straightforward and can appear paradoxical. For exam-
ple, tobacco smoking rates in those with schizophrenia are
typically twice those of the background population which
would suggest higher rates of lung cancer in those with
schizophrenia, but some studies quote a lower incidence of
lung cancer in people with schizophrenia (Hippisley-Cox
et al., 2007).
Overview of epidemiological studies
exploring the relationship between
cancer and schizophrenia
Incidence
In 1909 The Board of Control of the Commissioners in
Lunacy for England and Wales (1909) noted the possibility
of a decreased incidence in cancer among psychiatric patients.
Subsequent studies undertaken in the following three decades
appeared to conﬁrm these ﬁndings, although these results
were based upon proportionate mortality ratios which can
be misleading because important confounders are not con-
trolled for (Cohen et al., 2002). These early studies were fol-
lowed by more sophisticated studies which compared selected
groups of psychiatric inpatients with the general population
in their respective countries and failed to conﬁrm the earlier
ﬁndings of a decreased cancer incidence.
Mortensen (1989) followed a cohort of 6168 Danish
patients with schizophrenia for nearly 30 years and concluded
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jop.sagepub.comthat the overall incidence of cancer was lower for men with
schizophrenia than the general population but the same for
females with schizophrenia. Mortensen (1994) was able to
control for smoking and thereby address suggestions that
lower cancer rates in schizophrenia patients were related to
prohibitions on smoking in some psychiatric hospitals at cer-
tain times. Mortensen (1989) also speculated that psychotro-
pics had a protective eﬀect. Gulbinat et al. (1992) conﬁrmed
these ﬁndings in Denmark but not in two other study centres,
Honolulu and Nagasaki. No attempt was made to control for
age, smoking or other risk factors.
Cohen et al. (2002), in a study that controlled for many
confounding variables and utilized data from the 1986 US
National Mortality Followback Survey, found an odds ratio
(OR) of 0.59 (95% conﬁdence interval (CI) 0.38–0.93) for
schizophrenia patients developing cancer compared with gen-
eral population controls. Other modern studies have not rep-
licated these ﬁndings of a lower incidence of cancer. Ananth
and Burnstein (1977) demonstrated an increase in gastroin-
testinal tract cancers and breast cancer. Saku et al. (1995)
reported similar cancer incidence rates in the general and
schizophrenia populations. Lichtermann et al. (2001), using
the Finnish Cancer Registry, observed a total of 446,653 sub-
ject years and found an increased cancer rate. Nearly half this
excess related to lung cancer. However, cancer rates were
lower in non-psychotic siblings and parents than in the gen-
eral population, leading them to suggest that lifestyle factors
accounted for the increased cancer rate in those with schizo-
phrenia but that there was a protective eﬀect of schizophrenia
risk genes in those not showing the disease.
Catts et al. (2008) were the ﬁrst to publish a meta-analysis
of cancer incidence rates in those with schizophrenia and their
relatives. The overall standardized incidence rate (SIR) of
cancer in schizophrenia patients was the same as in the gen-
eral population but was lower in their siblings (SIR¼0.89, CI
0.84–0.94) and parents (SIR¼0.90, CI 0.88–0.93). In a large
study in the UK, Goldacre et al. (2005) also found similar
incidence rates in those with schizophrenia and the general
population. However, in this study they were unable to con-
trol for confounders which may have masked diﬀering inci-
dences such as smoking. They did, however, note a lower
incidence of skin cancer in those with schizophrenia.
Mortality
Historically, patients with schizophrenia have failed to beneﬁt
from the healthcare changes that have beneﬁted the general
population, such as improvements in the management of
tuberculosis (Odega ˚ rd, 1952). Tran et al. (2009), in an
11-year prospective follow-up study of a cohort of 3470
patients with schizophrenia, examined cancer-related mortal-
ity and predictors. They found a higher standardized mortal-
ity rate (SMR) for cancer in those with schizophrenia, and
the SMR for the two commonest cancers, namely lung in
men and breast in women, was 2.2 (95% CI 1.6–3.3) and
2.8 (95% CI 1.6–4.9), respectively. In the meta-analysis by
Saha et al. (2007), the category neoplastic disorder had a
median SMR of 1.37 but the authors observed that this was
relatively low compared with SMRs for other causes of death.
Brown et al. (2010) have reported increased SMRs for
patients with schizophrenia and breast or lung cancer in a
British cohort.
Assuming an incidence mortality gap exists, there are
many potential explanations. These range from factors intrin-
sic to schizophrenia or its treatment accelerating death from
neoplasm, to psychosocial eﬀects such as poor compliance
with treatment among patients with comorbid schizophrenia
receiving suboptimal treatment due to overt (stigma) or
covert (paternalism) discrimination.
Schizophrenia as a protective factor
Given the increased cancer risk factors for patients with
schizophrenia, such as smoking, physical inactivity and
poor diet, it is perhaps surprising that the literature is con-
fused (Table 1). The very fact that there is not a dramatic
increase in cancer rates suggests that schizophrenia may
aﬀord some protection. Genetic factors have been advocated
to explain the reduced risk, such as the p53 gene producing,
through apoptosis, the dual beneﬁcial eﬀects of disrupting
neurodevelopment and reducing the risk of cancer (Catts
and Catts, 2000; Cui et al., 2005; Park et al., 2004; Yang
et al., 2004).
Imprinting may also represent an epigenetic factor. Abel
et al. (2006) observed that a reduced rate of colorectal cancer
in schizophrenia, such as described by Goldacre et al. (2005),
may be related to abnormal insulin-like growth factor-2
(IGF-2) imprinting, which is aetiological in the development
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52 Journal of Psychopharmacology 24(11)of colorectal cancer (Jirtle, 2004). Abel et al. (2006) suggested
abnormal imprinting (deletion of paternally expressed IGF-2)
as a possible mechanism associated with schizophrenia risk
(Abel, 2004). Early nutritional inﬂuences (prenatal/maternal)
may stimulate changes in cytosine methylation to which
imprinted genes such as IGF-2 seem susceptible. Early nutri-
tion may also inﬂuence susceptibility to schizophrenia as well
as to adult obesity, diabetes and cardiovascular disease
(Waterland and Jirtle, 2004).
It has been speculated that schizophrenia is a disease of
accelerated aging (Kirkpatrick et al., 2008), which seems at
odds with the hypothesis that it may be cancer protective.
Generally, cancer is a disease of old age and it may be
simply that patients are not living long enough to be at sig-
niﬁcant risk (Figure 1). For example, 80% of cases of breast
cancer are diagnosed in women over the age of 50 years.
In addition, other factors complicate the interpretation of
these studies with regard to accelerated aging. Cancer is not
a single disease and has several diﬀerent aetiological pathways
that conﬂuence in the DNA mutation. Cells that have entered
senescence from normal aging are not prone to develop
cancer because they have reached an irreversible ‘stop’ in
the cell cycle (Dimri, 2005).
Cancer in the general population
In the UK in 2007 there were 155484 deaths from cancer.
Lung, bowel, breast and prostate cancers accounted for
22%, 12%, 8% and 7% of these deaths, respectively
(Table 2). Incidence and mortality ratios are higher in men
than in women. There is variation in the incidence of cancers
between racial groups (Devesa et al., 1999) and countries
(Wild et al., 2006), as well as in survival rates (Sant et al.,
2001). These persisting regional diﬀerences in survival rates
suggest there may be corresponding diﬀerences in the avail-
ability of diagnostic and therapeutic facilities and in the eﬀec-
tiveness of healthcare systems.
Numerous other factors inﬂuence the incidence of cancers,
such as smoking, exposure to other carcinogens, menopausal
status and lifestyle factors including exercise level, diet and
obesity. For example, in the UK, male lung cancer rates have
fallen by 46% from 113 per 100,000 in 1975 to 61 in 2006.
Over the same time period, female lung cancer incidence rates











































































































Figure 1. Number of new cases and rates, by age and sex, all malignant neoplasms, UK, 2006.
Table 2. The 20 most common cancers in the UK, 2006
Cancer Male Female Persons Total
Other 16,380 13,948 30,328 10.33%
Mesothelioma 1942 385 2327 0.79%
Cervix 0 2873 2873 0.98%
Liver 2015 1178 3193 1.09%
Multiple myeloma 2174 1813 3987 1.36%
Brain with central
nervous system
1921 2611 4532 1.54%
Oral 3540 1785 5325 1.81%
Ovary 0 6596 6596 2.25%
Uterus 0 7045 7045 2.40%
Leukaemias 4229 3008 7237 2.46%
Pancreas 3731 3929 7660 2.61%
Stomach 4970 2743 7713 2.63%
Oesophagus 5034 2790 7824 2.66%
Kidney 4879 2961 7840 2.67%
Bladder 7307 2957 10,264 3.50%
Melanoma 4803 5607 10,410 3.55%
NHL 5658 4911 10,569 3.60%
Prostrate 35,515 0 35,515 12.10%
Colorectal 20,430 17,084 37,514 12.78%
Lung 22,381 16,646 39,027 13.29%
Breast 314 45,508 45,822 15.61%
All 147,223 146,378 293,601
NHL, non-Hodgkin’s lymphoma.
Hodgson et al. 53are related to smoking rates. The histology of diagnosed lung
cancer is also changing, with an increase in adenocarcinoma,
which is the most common histological diagnosis in non-
smokers. This increase in adenocarcinomas may also be
related to the increase use of low-tar cigarettes (Franceschi
and Bidoli, 1999).
Many of these factors may be related to observations from
many countries showing a socioeconomic eﬀect on cancer
survival. In England and Wales, where healthcare is centrally
funded, patients from aﬄuent areas have increased survival
rates compared with those from disadvantaged areas, and this
deprivation gap widened for most cancers between the mid-
1980s and the late 1990s (Rachet et al., 2008; Richards, 2008).
These deprivation gaps may be avoidable after a time lag, and
testicular cancer provides an interesting example of this (Nur
et al., 2008; Richards, 2008). Five-year relative survival rates
in the most aﬄuent groups were near to reaching the ceiling
of 100% by 1996–1999, and survival rates for the most
deprived groups seem to have been catching up. In reviewing
England and Welsh survival data clinicians tended to explain
this survival gradient in terms of comorbidity, but epidemiol-
ogists were more likely to argue that late presentation and
diagnosis was more relevant (Richards, 2008). A strong socio-
economic eﬀect has also been demonstrated in Denmark,
another country where healthcare is centrally funded
(Dalton et al., 2008). This national register study of over
26 million patient-years showed poor survival mirrored socio-
economic adversity, including poor housing, unemployment,
limited education and the presence of SMI or depression.
Why should cancer rates be different
in those with schizophrenia?
Schizophrenia is a devastating illness with a prevalence of
around 0.7% and accounts for signiﬁcant morbidity. The
fact that this disease persists has led to speculation that the
genes or linkages that predispose to schizophrenia may also
confer advantage, and hence the persistence of a disease
which apparently confers a reproductive disadvantage.
A lower susceptibility to cancer may be one of these genetic
advantages. Table 1 describes some putative factors which
may aﬀect the incidence and mortality from cancer in the
schizophrenia population. The picture is complicated and
many of the listed factors can be both protective and confer
risk, as well as being inter-related. Just as schizophrenia is not
a single illness, cancer is a complex biological phenomenon
made up of more than 100 anatomical subtypes, many of
which are further divided into variants with diﬀering histol-
ogy, prognosis and response to treatment. Only some may be
modiﬁable by factors associated with schizophrenia.
Smoking and substance misuse
In general, patients with schizophrenia tend to smoke at twice
the rate of the background population (Kelly and McCreadie,
1999). The association between tobacco smoking and cancer
is well known, but the use of other noxious substances with
potential carcinogenicity is also higher in the schizophrenia
population. For example, alcohol is associated with cancers
of the oesophagus, and cannabis smoking exposes users to a
variety of carcinogens.
Exercise and diet
Exercise and diet are modiﬁable risk factors for many cancers.
While anecdotally patients with schizophrenia are described
as having poor diets and being physically inactive, there are
few studies investigating these parameters. McCreadie et al.
(1998) reported poor dietary habits in a case-control study,
with schizophrenia patients consuming signiﬁcantly less
energy, total ﬁbre, retinol, carotene, vitamin C, vitamin E
and fruit/vegetables than matched controls. Daumit et al.
(2005) surveyed outpatients with schizophrenia and aﬀective
disorders at two psychiatric centres in Maryland, United
States, and compared physical activity patterns with an age-
gender-race-matched national sample of the general popula-
tion. People with SMI were overall less physically active than
the general population, although the proportion with recom-
mended physical activity levels was equal. Participants with
SMI were more likely to walk as their sole form of physical
activity. Within the SMI group, those without regular social
contact and women had higher odds of being inactive. There
is strong evidence that physical activity and ﬁtness are cancer
protective (Kampert et al., 1996). Ruiz et al. (2008) showed
muscular strength is inversely and independently associated
with death from all causes and cancer in men, even after
adjusting for cardiorespiratory ﬁtness and other potential
confounders.
The number of SMI subjects who exercise appropriately is
low (Smith et al., 2007), and data in both adolescent and
treatment-naı¨ve psychosis populations have conﬁrmed that
this reduction in exercise precedes initiation of drug treat-
ments. There are some theoretical reasons, both treatment
and illness related, to the interaction of negative symptoms
and exercise. There has been little attention on improving
exercise rates, but where this has been attempted as part of
a lifestyle programme there have been impressive improve-
ments (Smith et al., 2007).
Diet in schizophrenia is also less than ideal as a result of
multiple factors ranging from cognition issues, knowledge
and money (McCreadie et al., 1998). Research from several
sources provides strong evidence that vegetables, fruits, whole
grains, dietary ﬁbre, certain micronutrients and some fatty
acids protect against some cancers. In contrast, other factors,
such as alcohol, some fatty acids and food preparation meth-
ods may increase risks (Greenwald, 2001).
Treatment effects
Since the 1950s, eﬀective biological treatments have been
developed for schizophrenia and these treatments may have
both direct and indirect eﬀects on cancer incidence and mor-
tality (Csatary, 1972). Many antipsychotics appear to have
anti-tumour properties in vitro (Carrillo and Benı´tez, 1999).
Pimozide and thioridazine (Strobl and Peterson, 1992) kill
cancer cells by blocking the synthesis or movement of choles-
terol and lipid in these cells. The addition of mevastatin, a
drug that inhibits cholesterol production in cells, augmented
this eﬀect. Phenothiazines have also been shown to have
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extrapolating controlled laboratory ﬁndings to the real
world is diﬃcult given the many potential confounders.
Nevertheless, Hippisley-Cox et al. (2007) showed a non-sig-
niﬁcant statistical increase in the risk of colon cancer with
antipsychotics. Harlow et al. (1998) studied the eﬀect of psy-
chotropic medication exposure on epithelial ovarian cancer
incidence, and found that any association was largely con-
ﬁned to use of medications that operate through dopaminer-
gic mechanisms (OR 2.9; CI 1.3–6.4) or gabaergic pathways
(OR 1.5; CI 0.9–2.5) as opposed to serotoninergic pathways
(OR 1.0; CI 0.4–2.1). A case–control study of endometrial
cancer after antipsychotics exposure in premenopausal
women (Yamazawa et al., 2003) reported that the use of anti-
psychotics, diabetes mellitus and obesity were identiﬁed as
independent variables with risk estimates of 5.4, 9.3 and
4.9, respectively.
Hyperprolactinaemia
While antipsychotics may have anti-tumour properties, they
also cause side eﬀects which may have the opposite eﬀect.
Hyperprolactinaemia is a common side eﬀect for ﬁrst gener-
ation and some second generation antipsychotics such as ris-
peridone and amisulpride (Bushe and Shaw, 2007; Bushe
et al., 2008; Kahn et al., 2008). Initially, hyperprolactinaemia
was an occult side eﬀect but it is now recognized as a cause of
amenorrhoea, galactorrhoea, sexual dysfunction, and osteo-
porosis and bone fractures (Abel et al., 2008; Howard et al.,
2007; Kohen and Wildgust, 2008). While raised prolactin
levels are known to promote rodent mammary carcinogenesis
and transition to invasive carcinoma, a link between human
breast cancer and hyperprolactinaemia was initially dis-
counted (Harvey et al., 2008). In part this was due to the
putative protective eﬀect of neuroleptics, diﬀerences between
rodent and human endocrinology and the failure of human
tumours to respond to prolactin-lowering drugs such as bro-
mocriptine (Harvey et al., 2008). However, there is increasing
evidence linking elevated prolactin levels to human breast
cancer in the general population (Tworoger et al., 2004,
2007). The large-scale epidemiological US nurses’ study
reported an increased risk associated with normal prolactin
levels when comparing breast cancer incidence in the upper
versus lower quartile of normal levels (Tworoger et al., 2004,
2007). Wang et al. (2002) found an increase of 16% in the risk
of breast cancer among women who had used antipsychotics
and other prolactin-elevating drugs such as some anti-eme-
tics. Furthermore, this relationship showed a dose response.
Peveler et al. (2008) stated that hyperprolactinaemia should
be considered when starting an antipsychotic in a woman
with a personal or family history of breast cancer.
Szarfman et al. (2006) described a disproportionality in
reported incidence of hyperprolactinaemia, galactorrhoea
and pituitary tumours between seven widely used antipsy-
chotic drugs. The role of hyperprolactinaemia in prostate
cancer is unclear, but the eﬀects of prolactin on prostate
cancer cells are similar to those in breast cancer cells
(Harvey et al., 2008). Compared with breast cancer, few clin-
ical studies have been undertaken and a potential confounder
is whether a high prolactin level is a cause or an eﬀect of
prostate cancer. One small study of 50 men with metastatic
disease did show a relationship (Lissoni et al., 2005), but a
prospective case-control study of 144 men with prostate
cancer matched with 289 controls revealed no relationship
(Stattin et al., 2001).
Obesity
Obesity is described as a modiﬁable risk factor for cancer and
increases the risk of cancers including cancers of the breast
(postmenopausal), endometrium, colon, kidney and oesoph-
agus. Research suggests that maintaining a healthy weight
conveys the greater protective eﬀect, but weight loss has
been shown to be beneﬁcial in reducing breast cancer risk
(Harvie et al., 2005; Parker and Folsom, 2003). However,
the eﬀects of weight cycling are less well understood, with
one small study (Luo et al., 2007) showing an increased
kidney cancer risk in women who went through 10 or more
episodes of varying their weight by 10lbs or more.
Patients with schizophrenia may be metabolically obese in
spite of a normal body mass index (BMI) (Thakore, 2004).
Antipsychotics and antidepressants may predispose patients
to weight gain, and patients with schizophrenia are more
likely to have centripetal obesity which predisposes to certain
cancers such as bowel (Dai et al., 2007) and breast (Connolly
et al., 2002). Proposed mechanisms by which obesity may
predispose to cancer risk include through glucose metabolism
and, especially in the case of breast and endometrial cancer,
through hormonal mechanisms. Other mechanisms are also
relevant, such as obesity increasing the risk of oesophageal
cancer by causing gastric acid reﬂux (Freeman, 2004) and
increasing the risk of gallstones, which in turn increase the
risk of gallbladder cancer (Larsson and Wolk, 2007). Obesity
may be a consequence of or a cause of physical inactivity and
an unhealthy diet.
Obesity is just one feature of metabolic syndrome; some
other components including hypertension and diabetes may
also confer an increased risk of cancer. Grossman (2002)
systematically reviewed the literature and reported that in
prospective studies, patients with hypertension experienced
an increased rate of cancer mortality (follow-up period 9–20
years), with an age- and smoking-adjusted pooled OR of 1.23
(95% CI 1.11–1.36). In 13 case–control studies, including
6964 cases of renal cell cancer and 9181 controls, the adjusted
OR for renal cell cancer among hypertensive patients, relative
to normotensive counterparts, was 1.75 (95% CI 1.61–1.90).
Obesity is a risk factor for diabetes, and there is a develop-
ing epidemiological literature suggesting an association
between history of metabolic syndrome/diabetes and risk of
developing a variety of cancers (Za ¨ nker, 2008). This suggests
that metabolic syndrome/diabetes mellitus type 2 are associ-
ated with an increased risk of cancer, or are even independent
predictors of mortality from hepatocellular carcinoma and
cancer of the colon and pancreas in men and women, as well
as cancer of the breast and endometrium in women and liver
and bladder in men. However, the association is complex, with
some studies showing a lower risk of cancer among patients
with diabetes; for example, Waters et al. (2009) found a lower
risk of prostate cancer in diabetic than in non-diabetic
subjects. An association between diabetes, hyperinsulinemia,
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obesity, adipokines, Western-style dietary habits and carcino-
genesis appears plausible. Furthermore, increased blood
sugars are associated with an increased mortality (Stocks
et al., 2009). Stocks et al. (2009) described raised blood glucose
as a risk factor for cancer that was independent of obesity and
smoking. The increased prevalence of diabetes in patients with
schizophrenia in an increasingly obesogenic society should be
seen as a public health concern.
Obstetric factors
The risk of schizophrenia is inﬂuenced by birth order,
although ﬁndings are not entirely consistent. Kemppainen
et al. (2001) demonstrated increased risk of schizophrenia in
male ﬁrst-borns (OR 1.5; 95% CI 1.0–2.2) and last-born
females (OR 1.3; 95% CI 0.9–1.9). Male ﬁrst-borns are also
at higher risk of testicular cancer (Cook et al., 2009). These
ﬁndings may suggest that patients with schizophrenia may be
at increased risk of testicular cancer; Goldacre et al. (2005)
have shown higher rates of testicular cancer in schizophrenia
(OR 1.30; 95% CI 0.35–3.39), but there are too few cases to
draw conclusions.
Decreased birth weight is also a risk factor for schizophre-
nia, as well as for cardiovascular disease. Furthermore, recent
research suggests that low birth weight may be a risk factor
for malignancy. Very low birth weight was associated with an
increased risk of certain types of paediatric brain cancer, such
as some gliomas (Spector et al., 2009). However, if breast
cancer is considered, a diﬀerent conclusion is reached. In a
meta-analysis of 18 studies (16,424 breast cancer cases) (Xu
et al., 2009), women with a birth weight of less than 4000g or
8.5lb had a higher risk for developing breast cancer than
those with birth weight less than 2500g or 3000g (OR 1.20,
95% CI 1.08, 1.34). These ﬁndings were also consistent with a
dose-response pattern eﬀect. Breast cancer is described as
hormone sensitive, but in another hormone-sensitive cancer,
endometrial cancer, there was no evidence of a link between
birth weight and incidence (Lo ¨ f et al., 2007). In addition, this
study of 38,566 Swedish women demonstrated the protective
eﬀect of low birth weight on breast cancer risk.
Methodological issues
Introduction/overview
Cancer is, in general terms, an illness diagnosed in patients
aged over 50 years. Some of the complexity in interpreting
dissonant cancer data can be explained by the simple metric
that few current studies have been able to include and follow
cohorts that are age appropriate. For example, cancer data in
ﬁrst-episode subjects may be of lesser clinical utility and
require potentially immense powering to demonstrate signif-
icant diﬀerences. Often the cancers studied are not the most
prevalent in this age group, such as leukaemia. Furthermore,
cancer, like schizophrenia, is not a unitary disease. Even in
one organ there are many potential cellular types, each with a
diﬀerent aetiology and prognosis.
Breast cancer
Breast cancer is the most common cancer in women, with a
lifetime risk of 1 in 9 in the general population. Incidence
rates increase markedly with age, with 80% of cases diag-
nosed in women aged over 50 years (Oﬃce for National
Statistics, 2007). This high lifetime risk should facilitate epi-
demiological studies, and a recent systematic review identiﬁed
over 400 reports (Bushe et al., 2009). However, when preset
quality indicators were applied, only 13 studies were judged to
be of suﬃcient quality. One identiﬁed quality indicator was
the inclusion of more than 100,000 patient-years follow-up
(Baldwin et al., 1987). Studies not achieving this threshold
tended to report no diﬀerence in breast cancer rates between
the general population and those with schizophrenia. Studies
with greater patient-years, and therefore better powered to
account for confounders, generally found a higher incidence








Dupont et al. (1986) Denmark 3196 , 102 1957–1980 SIR 1.09 (0.89–1.33)
Nakane and Ohta (1986) Japan 1388 , 6 1960–1978 RR 3.23 (1.16–6.87) p<0.01. In ,s<53 years at study end
RR 8.06 (2.62–18.82) p<0.001
Mortensen (1989) Denmark 3196 ,< 125 ,,2< 1957–1984 IRR 1.19 (ns) ,s IRR 1.19 ,s and <s( p<0.05)
Gulbinat et al. (1992) 2779 , Not stated 1962–1980 SIR 1.6 (0.52–3.74)
Mortensen (1994) Denmark 3498 , 22 1970–1987 SIR 0.88 (non sig)
Lichtermann et al. (2001) Finland 11,418 , 152 1971–1996 SIR 1.15 (0.98–1.34)
Dalton et al. (2003) Denmark 7541 , 74 1970–1997 RR 0.90 (0.71–1.12)
Barak (2005) Israel 1247 , 22 1993–2003 SIR 0.60 (0.37–0.90)
Dalton et al. (2005) Denmark 9743 , 215 1969–1993 SIR 1.2 (1.05–1.38)
Goldacre et al. (2005) UK 9649 ,< 80 1963–1999 Adjusted rate ratio 1.01 (0.80–1.26)
Grinshpoon et al. (2005) Israel 33,372 , 370 1962–2001 SIR total, 1.11 (1.00–1.22)
Hippisley-Cox et al. (2007) UK 49 1995–2005 Adjusted OR 1.52 (1.10–2.11)
Barak et al. (2008) Israel 2011 , 51 1960–2005 SIR 0.63 (0.47–0.83)
IRR, incidence rate ratio; RR, relative risk; SIR, standardized incidence ratio.
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The three largest studies, Grinshpoon et al. (2005),
Lichtermann et al. (2001) and Dalton et al. (2005), report
SIRs (95% CIs) of 1.11 (1.00–1.22), 1.20 (1.05–1.38) and
1.15 (0.98–1.34), respectively.
The largest risk is in the cohort with median age 61 years
at cancer diagnosis (OR 1.52; 95% CI 1.10–2.11)
(Hippisley-Cox, et al., 2007). This was a nested, case-control
study and thus diﬀers from all other included studies.
In reviewing the literature, Bushe et al. (2009) also highlight
the diﬃculties posed in this area of research. There are many
potential confounders to account for, including age, parity,
menopausal status, contraceptive history, obesity, smoking
history and dietary history. Most published research relies
on national disease databases, which are only maintained in
a few countries and, as Bushe et al. (2009) identiﬁed, there is
potential double counting in meta-analysis as published
papers may have used subjects from the same population.
Even in national cohorts of a common cancer such as
breast, the absolute number of actual cases is small.
Epidemiological studies cannot generally investigate histolog-
ical tumour type, so it is unclear as to whether the distribution
of breast cancers in women with schizophrenia follows that in
the general population.
Access to healthcare
In the UK there is evidence that people with schizophrenia do
consult with their general practitioner (Harvey, 1996).
However, they may not beneﬁt from these consultations.
Observational studies show high rates of hypertension and
dyslipidaemias, but also that prescribing rates of anti-hyper-
tensives and statins are far lower than would be expected
(Strom et al., 2008). In a Danish cohort study of cardiovas-
cular outcomes, Laursen et al. (2009) observed that patients
with SMI were far less likely to receive invasive cardiac pro-
cedures than matched controls, which probably explained
their lower life expectancy. Kisely et al. (2007) reported sim-
ilar ﬁndings from a study in Novia Scotia, Canada. Two
Canadian studies exploring uptake of cervical (Martens
et al., 2009) and breast cancer screening (Chochinov et al.,
2009) showed lower rates for those with schizophrenia.
A study of mammography screening from the UK was
slightly more optimistic for those with mental illness in gen-
eral, but highlighted SMI as a risk factor for lower uptake
(Werneke et al., 2006). Kisely et al. (2008) also demonstrated
that people with mental illness in Nova Scotia had an
increased mortality from cancer, which could not be
explained, for example, by an increased incidence. They spec-
ulated that this excess mortality was caused by delays in
detection or initial presentation leading to more advanced
staging at diagnosis, and diﬃculties in communication or
access to healthcare.
Relevance to psychiatric clinical practice
While some psychiatrists will not see the physical health of
their patients as their concern, or indeed, within their compe-
tence (Kick et al., 1997), the overwhelming evidence of poor
physical health in those with schizophrenia makes such a
stance diﬃcult to justify (Hodgson and Adeyemo, 2004).
Guidance from the UK’s National Institute of Clinical
Health (NICE, 2009) places primary care centrally in physical
healthcare but outlines what is expected from mental health
services in helping patients access these services.
Psychiatrists can play a preventative role and encourage
patients to review lifestyle risk factors such as a sedentary
lifestyle, poor nutrition, smoking and obesity. Tackling
these issues not only reduces cancer risk factors but
also those associated with cardiovascular disease. Of course,
there are also other tangible beneﬁts to be achieved by
attention to lifestyle. Smoking cessation interventions may
potentially reap the greatest rewards in improving physical
health. While our review would suggest that certain cancers
are more prevalent in the schizophrenia population and
others less prevalent, this does not mean a complacent atti-
tude can be adopted for the latter.
Mental health professionals need to encourage patients to
make use of appropriate screening opportunities and to sup-
port them through a healthcare system that may seem daunt-
ing if a malignancy is discovered, in order to maximize
outcomes. Even though cancer is a common cause of death,
it is still primarily a disease of older people. However, while
psychiatrists will see fewer patients with cancer than many
other non-cancer specialists, this should not dissuade them
from advocating for their patients.
Conclusions
This overview has highlighted the complexities of research in
this area. There are many methodological considerations for
epidemiological studies relating to cancer risk and schizophre-
nia. The potential number of confounders makes unravelling
clinically signiﬁcant associations diﬃcult unless very large
samples are used. Many of these confounders will vary tem-
porally, such as relatively recent trends in obesity. A greater
comprehension of the genetics and molecular mechanisms of
cancer and schizophrenia may also reﬁne our understanding
of any relationship between these disorders, and also poten-
tially focus epidemiological research with a greater under-
standing of phenotypes and genotypes. The recent unveiling
of a cancer genome and the considerations that advances in
epigenetic factors underline the complexities of research in
this area.
If the risk of certain tumours is found to diﬀer between the
general and the schizophrenia population, this should aid tar-
geting at risk populations for screening, as is seen in the
Canadian Diabetic Guidelines where schizophrenia is seen as
deﬁning an at-risk group. However, some patients with schizo-
phrenia will still need help in accessing appropriate screening
and oncology treatment services if a reduction in mortality is
to be achieved. If some cancers do have a lower incidence in
schizophrenia; this does not mean they can be ignored. Even if
there is a decreased risk of cancer, it should be remembered
that patients with schizophrenia are still at an increased risk of
metabolic and cardiovascular disease, and many of the risk
factors for these disorders overlap with those for cancer.
From a pragmatic perspective, the practising clinician
should be mindful of the mortality gap in schizophrenia
and be vigilant for somatic health problems in their patients.
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